Diabetes Mellitus, Type 2 Clinical Trial
— ANODE01Official title:
A Single-centre, Open-label Study Testing the Safety and Performance of the Glyconics-SX System in Individuals With or Without Type 2 Diabetes
Verified date | October 2023 |
Source | Glyconics Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The main clinical study objective is to retrieve initial high quality spectra measurements indicative of the accuracy of the Glyconics-SX System in distinguishing between individuals with or without T2DM based on known and/or assumed clinical status of the participants and as controlled by values of an internal biomarker indicative of glycaemia, HbA1c, as measured with validated, comparator device.
Status | Completed |
Enrollment | 100 |
Est. completion date | October 28, 2022 |
Est. primary completion date | October 19, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Apparently healthy adults (=18 years of age) with known or unknown T2DM status willing to participate in and provide a written consent for the study - willingness to undertake assisted assessment of glycaemia by both the NIR spectra measurement, and HbA1c by finger prick test - Individuals with two visually assessed apparently healthy, undamaged, and intact fingernails, one in both right- and left-hand middle fingers Exclusion Criteria: - Individuals with any known medical conditions impacting either of the assessment methodology for glycaemia, such as - anaemia (iron deficiency sickle cell anaemia or similar) - haemoglobinopathies or atypical haemoglobin subtypes not detectable by regular assays, - severe renal impairment (CKD stage III-IV) or decompensated hepatic disease - severe Vitamin D deficiency - known severe immunodeficiency such as HIV, malignancy or other chronic condition significantly impacting assessment of glycaemia - eating disorders (as per clinical assessment) - Recent (within 28 days) blood donation - Any structural, deviating and visually detectable deviations in the appearance of the nails potentially impacting the spectra measurement, including - nail dystrophy or deformity - severe nail infections (onychomycosis causing visual changes in the appearance of the nail) - rare hereditable conditions impacting the structure of keratin - mechanical damage or marks on the surface of the nail after removal of nail polish - use of acrylic or gel nail decoration and polish, which cannot be removed - Any systemic or topical medication known to modify either the surface or structure of the nail or accuracy of HbA1c value. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Leicester Diabetes Centre | Leicester |
Lead Sponsor | Collaborator |
---|---|
Glyconics Ltd |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Accuracy of the Glyconics-SX System in detection of DM status based on dichotomised outcomes as per the chemometric model (HbA1c measurements as internal control) | Overall probability of correct classification by the chemometric model output (yes / no DM) | 60 seconds | |
Secondary | Assessment of sensitivity and specificity for chemometric model outcomes | False positive and false negative assessments in % | 60 seconds | |
Secondary | Calculation of negative and positive predictive value for the chemometric model | Calculated values in % | 60 seconds | |
Secondary | Calculation of area under the curve (AUC) with axis defined by false positive and negative rates (FPR, FNR) for the chemometric model | Area under the curve value | 60 seconds | |
Secondary | Median (IQR) HbA1c values in both groups (with or without diabetes) as measured by the comparative device | HbA1c value in mmol/mol | 4 minutes | |
Secondary | Analysis of safety outcomes (AEs, SAEs), including any safety outcomes listed in the comments, such as potential, suspected de novo diabetes diagnosis cases based on HbA1c readings | Adverse events | 15 minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
Recruiting |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |